II. The Question of Castration for Enlarged Prostate.
作者信息
Cabot A T
出版信息
Ann Surg. 1896 Sep;24(3):265-309. doi: 10.1097/00000658-189607000-00036.
Abstract
摘要
相似文献
1
II. The Question of Castration for Enlarged Prostate.二、前列腺肿大的阉割问题。
Ann Surg. 1896 Sep;24(3):265-309. doi: 10.1097/00000658-189607000-00036.
2
I. The Question of Castration for Enlarged Prostate.一、前列腺肿大的阉割问题。
Ann Surg. 1896 Sep;24(3):388-98. doi: 10.1097/00000658-189607000-00042.
3
Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective.去势抵抗性前列腺癌的适应和克隆选择模型：当前观点。
Int J Urol. 2013 Apr;20(4):362-71. doi: 10.1111/iju.12005. Epub 2012 Nov 19.
4
Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride.给予5α-还原酶抑制剂非那雄胺的大鼠腹侧前列腺中萎缩和凋亡的证据。
Endocrinology. 1995 Feb;136(2):741-8. doi: 10.1210/endo.136.2.7835306.
5
[Establishment of prostatic hyperplasia model with castration beagle canines].[去势比格犬前列腺增生模型的建立]
Zhonghua Nan Ke Xue. 2003 Sep;9(6):425-8.
6
Expression and localization of transforming growth factor-beta receptors type I and type II in the rat ventral prostate during regression.
Mol Endocrinol. 1996 Jan;10(1):107-15. doi: 10.1210/mend.10.1.8838150.
7
Progressive enlargement of prostatic nodule after castration.去势后前列腺结节进行性增大。
JAMA. 1976 Dec 6;236(23):2669.
8
Nuclear receptor profiling in prostatospheroids and castration-resistant prostate cancer.前列腺小体和去势抵抗性前列腺癌中的核受体谱分析。
Endocr Relat Cancer. 2018 Jan;25(1):35-50. doi: 10.1530/ERC-17-0280. Epub 2017 Oct 17.
9
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.醋酸阿比特龙和泼尼松龙用于对雄激素剥夺和多西他赛化疗无效的转移性去势抵抗性前列腺癌：一项针对韩国和台湾患者的II期衔接性研究。
Int J Urol. 2014 Dec;21(12):1239-44. doi: 10.1111/iju.12589. Epub 2014 Aug 6.
10
Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.阿糖胞苷治疗多西他赛耐药去势抵抗性前列腺癌的 II 期研究，同时评估 TMPRSS2-ERG 和 SPINK1 作为血清生物标志物。
BJU Int. 2012 Sep;110(6):840-5. doi: 10.1111/j.1464-410X.2011.10922.x. Epub 2012 Feb 7.
引用本文的文献
1
Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.在良性前列腺增生小鼠模型中，去势诱导的前列腺基质消退率降低。
Am J Clin Exp Urol. 2023 Feb 25;11(1):12-26. eCollection 2023.
2
Testosterone Therapy in Men With Prostate Cancer.前列腺癌男性的睾酮治疗
Eur Urol. 2016 May;69(5):894-903. doi: 10.1016/j.eururo.2015.12.005. Epub 2015 Dec 21.
3
Lower urinary tract symptoms in men.男性下尿路症状
BMJ. 2014 Aug 14;349:g4474. doi: 10.1136/bmj.g4474.
4
The Hormonal Treatment of Prostatic Malignancy.前列腺恶性肿瘤的激素治疗
Bull N Y Acad Med. 1946 Feb;22(2):88-101.
5
Carcinoma of the Prostate: Recent Advances in its Treatment.前列腺癌：其治疗的最新进展
Cal West Med. 1943 Feb;58(2):71-3.
6
Estrogenic side effects of androgen deprivation therapy.雄激素剥夺治疗的雌激素副作用。
Rev Urol. 2007 Fall;9(4):163-80.
7
Combination medical therapy for lower urinary tract symptoms and benign prostatic hyperplasia.下尿路症状与良性前列腺增生的联合药物治疗
Rev Urol. 2005;7 Suppl 8(Suppl 8):S43-51.
8
Treatment options in hormone-refractory prostate cancer: current and future approaches.激素难治性前列腺癌的治疗选择：当前与未来的方法
Drugs. 2001;61(15):2177-92. doi: 10.2165/00003495-200161150-00003.
9
Endocrine and adrenergic pharmacological intervention in diseases of the prostate.前列腺疾病的内分泌与肾上腺素能药理学干预
Br J Clin Pharmacol. 1998 Apr;45(4):329-37. doi: 10.1046/j.1365-2125.1998.t01-1-00688.x.
10
Benign prostatic hyperplasia. Practical treatment guidelines.良性前列腺增生。实用治疗指南。
Drugs Aging. 1997 May;10(5):349-66. doi: 10.2165/00002512-199710050-00004.
Zotero 插件